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The genome era in medicine is upon us. Questions that arise from patient and family care are a
watershed for research and technology, which in turn fuel the cycle of opportunity for impact
through delivery of health services, which feeds back to families. Medical infrastructure needs to
adapt to the dramatic pace of technology development in the wake of the Human Genome Project,
in order for genome data to be delivered as information and applied as knowledge to benefit health.
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G Ge en no om me es s   t to o   m me ed di ic ci in ne e
Medical practice and research have entered the genome era.
The evolution from medical genetics to genome medicine (or
genomic medicine) has been gradual and reflects a continuum
[1,2], but there has been a marked transition in the few years
since the completion of the first human reference genome
sequences [3,4]. From a predominant focus on single genes
and disease-related mutations has emerged the technology
to assay the genome in its entirety - with genotyping arrays
or sequencing - and the first means to interpret findings in a
comprehensive manner. The application of genomic medicine
involves diagnosis, prognosis, prevention and/or treatment
of disease and disorders of the mind and body, using
approaches informed by knowledge of the entire diploid
genome and the molecules it encodes. The foundations of
genetics as the study of heredity become illuminated when
individual genes are seen in the context of the whole genome
and environmental influences.
Our growing understanding of the human genome and the
processes it directs strengthens the foundation for this new
paradigm in biomedicine. The term ‘directs’ quite explicitly
describes the role of the genome with respect to phenotype,
and the distinction from ‘determines’ is critical. Par-
ticularly in the transition to a genomic focus in medicine,
we recognize factors that are individually more modest in
their impact than those highly penetrant alleles amenable
to earlier genetic analyses. Beyond the influence of the
context of the full genome, there is interaction with
epigenetic and non-genetic elements from the environment
and experience.
The cyclical nature of genome investigation is driven by a
constant flow of knowledge between medical practice and
research (both ‘bench to bedside’ and ‘bedside to bench’ [5]).
A conceptual analogy can be made with another natural
cycle: the water cycle (Figure 1). In such a model, genome
investigation guides informed research questions, which
yield solutions that feed back to individuals, families and
populations in a natural progression, and which have an
impact on health. The genome informs the patient, and the
patient informs the genome.Genomic medicine reflects not just a quantitative change in
approach (single genes to many genes), but also various
qualitative shifts in focus [1]. In these early days of whole-
genome assays, efficiency of data collection may be
enhanced, but the interpretation of findings still tends to be
in terms of discrete gene loci, and the meaning of
independent variations in the sequence. From among a list
of variant findings, the question still seems to be: ‘Which
one of these is a good candidate for causing the disease in
question?’ In time, the reductionist approach will give way
to one that is more holistic, when advanced analytical tools
will facilitate questions more like: ‘What is this overall
pattern of observations telling us about this individual, in
this situation, at this time?’ A second qualitative shift is
from the (often serial) hypothesis-driven approaches of
genetic investigation, to the relatively hypothesis-free
gathering of data from genomic sequence, somatic muta-
tions or whole cells. Evidence of variation from such large
datasets can then lead to comprehensive hypotheses of
medical relevance for further consideration. Part of the
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The cycle of patient- and genome-informed questions and answers in medicine. Set against familiar images depicting the water cycle, this analogy
emphasizes the natural flow of such a process and the influence of environmental factors. The ground(work) of the genome medicine cycle is the front-
line work directly with patients, families and populations. This feeds into the sea of questions to be addressed from clinical or research perspectives.
Investigators work to illuminate the questions, and the research process raises information to a relatively amorphous position of potential impact.
Information can be converted to knowledge and delivered through various conduits to patient care, which includes aspects of diagnosis, prediction and
intervention, thereby maintaining the cycle.
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of knowledgecomprehensiveness involves interpretation of the diploid
aspects of the genome.
Our growing understanding of the human genome and the
processes it directs forms the foundation for this new
paradigm in biomedicine. We recognize that medicine has
moved into a genomic era by the evidence of changes and
developments since the Human Genome Project [6] and
some of these, along with a few new projections of
developments yet to come, are described in Box 1. There are
already increased opportunities to: (i) predict an individual’s
risk of particular disease, (ii) detect disease early and
preempt its progression, (iii) provide individualized pharma-
cological agents and doses and other preventive inter-
ventions, (iv) anchor an individual’s genomic data to
complete health care information, and (v) provide new
resources and answers to families, investigators and care
providers to maximize health benefits. Nevertheless, the
greatest potential is yet to be realized.
Microarrays and targeted sequence analyses are already well
established, not only for research, but also for clinical diag-
nosis [7]. Arrays have become particularly helpful in the
diagnostic investigation of children with global develop-
mental delay, for whom sequential, hypothesis-driven assays
had often been uninformative [8]. The technical practicality
of routine individual whole-genome sequencing is in sight
[9]; this is the method with the highest resolution in
gathering information for genome-based medicine. Clearly,
however, this is a situation in which technology is well ahead
of the means by which to handle the onslaught of
information overload that is about to ensue [10,11]. This is
where the greatest anticipation and attention are needed.
Many examples cited as benefits to be anticipated from
genomic and individualized medicine pertain to common
conditions of (typically) adult onset, such as cancer, heart
disease, diabetes and susceptibility to infectious agents [12-14].
Pharmacogenomics is, of course, a realm with many exciting
promises [13,15,16]. From our experience in a primary care
pediatric hospital setting, we recognize numerous potential and
newly realized benefits for newborns, children and young
adults, as well as for their families. In one large study at a
pediatric hospital, more than two-thirds of admissions, and
fully 96% of those for chronic medical conditions, were
identified as involving a recognizable genetic component [17].
Below, we provide vignettes based on our personal experi-
ences in genome medicine. These come from professionals
whose primary responsibilities include genetic counseling,
pediatric genetics, prenatal genetics, DNA diagnostics,
pediatric oncology and genomic research. These stories
illustrate how a priori knowledge of the genome has directed
(or could have directed) medical treatment decisions, and
how questions arising from patients and families have
spawned new research initiatives.
C Ca as se e   A A: :   M Mi ic cr ro oa ar rr ra ay y   r re ev ve ea al ls s   v va ar ri ia an nt ts s   t th ha at t   s su ug gg ge es st t   t th he er ra ap pe eu ut ti ic c
p po ot te en nt ti ia al l
‘A’ was first assessed at age 17 years, when admitted to
hospital with severe back pain caused by multiple spinal
neurofibromas. He also had moderate global developmental
delay, attributed to a difficult delivery. Neurofibromatosis
type 2 (NF2) was considered, but he did not meet the clinical
criteria for this disorder. Initial investigations included
karyotype and DNA testing for fragile X syndrome and NF2,
all with normal results. Three years later, microarray testing
revealed a 20 kb loss at 2q22.1 in his genome, involving the
intron of THSD7B (thrombospondin type I). The specific
function of this gene is not known, but the protein family is
involved in angiogenesis, apoptosis and immune regulation.
In addition, a 43 kb duplication was found at 7q33, over-
lapping an aldo-keto reductase gene, AKR1B10. Mutations in
this gene lead to overexpression (cellular proliferation) and
have been found in several cancer and precancerous lesions.
Its activity seems to be inhibited by tolrestat [18], a drug
approved for control of some diabetic complications; there-
fore, the microarray results have potential implications for
medical treatment. We are now determining whether a
parental balanced structural variant could underlie the
findings in A, as this would have implications for recurrence
risks in other family members.
C Ca as se e   B B: :   ( (E Ep pi i) )g ge en no om mi ic c   a as ss sa ay ys s   s so ol lv ve e   a a   d di ia ag gn no os st ti ic c   d di il le em mm ma a   a an nd d
b by yp pa as ss s   t th he e   n ne ee ed d   f fo or r   t tu um mo or r   s su ur rv ve ei il ll la an nc ce e
Infant ‘B’ was referred for assessment regarding asymmetric
growth of his legs, with a discrepancy of 2.5 cm, and which
orthopedic evaluation interpreted as hemihyperplasia. In the
genetics clinic, however, it was difficult to determine by
physical examination whether the asymmetry represented
overgrowth on one side (hemihyperplasia) or undergrowth
on the other side (hemihypoplasia). The distinction is signi-
ficant, as children with hemihyperplasia are at increased risk
for embryonal tumors - notably, Wilms tumor and hepato-
blastoma; therefore, tumor surveillance is recommended,
consisting of quarterly abdominal ultrasounds and blood
work. B’s short stature suggested a diagnosis of Russell-
Silver syndrome (RSS), but findings were insufficient to
assign this clinical diagnosis. Recently, at age 4, new testing
by multiplex ligation probe-dependent amplification and
methylation array revealed a loss of methylation in the H19
gene, which encodes an imprinted maternally expressed
non-protein coding transcript, a finding associated with RSS
[19]. Given this genomic information, costly tumor surveil-
lance is no longer indicated, and the family’s anxiety is
greatly relieved.
C Ca as se e   C C: :   A A   l li if fe e   t th ha at t   m mi ig gh ht t   h ha av ve e   b be ee en n   s sp pa ar re ed d   b by y   g ge en no om mi ic c
s sc cr re ee en ni in ng g
‘C’ was 19 when he collapsed and died during a hockey game.
An autopsy revealed that he had succumbed to autosomal
dominant arrhythmogenic right ventricular cardiomyopathy
(ARVC, which has a prevalence of about 1 in 1,000), and
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Box 1. Evidence of the genome era in medicine
The announcement of a ‘finished’ version of the human genome sequences [6] marked both the conclusion of the Human Genome
Project and the beginning of the genome era in medicine and health care [29]. At that time, many predictions were made about the
short- and long-term transformation of medical practice. Considering the first five years since this milestone, we see the following
changes (some anticipated [1,12,30] and some not), and we forecast more to come.
Developments anticipated from the Human Genome Project
• The term ‘genome’ has become (somewhat) familiar to the general public.
• Beyond the reference genome sequence, the Human Genome Diversity [31] and HapMap projects [32] have provided seminal
information on individual and ethnic variation. Two additional genome sequences from single individuals [33,34] and those of
many other species for comparison [35] have been published.
• Microarray technologies, including whole-genome scans, are now broadly implemented by research and service laboratories and are
blurring traditional distinctions between cytogenetics and molecular genetics disciplines.
• Through the internet, information about genomic medicine has become far more accessible for scientists, health care providers and
the public.
• Research focus is shifting beyond genetic factors with high penetrance to those that can impart relatively small risk for common and
complex disorders.
• With enhanced sensitivity and resolution of newer technologies, information to be delivered to patients and families is becoming
more complex, with added elements of uncertainty and an emphasis on risk prediction.
• Genetic testing is becoming routine in many areas of medicine.
• Functional genomics is defining the importance of intergenic DNA sequences.
• Bioinformatics tools are beginning to allow more comprehensive interpretation of genomic data.
• Decreased cost is allowing comprehensive assays (such as whole-genome scanning or sequencing) to replace individual targeted
assays for diagnostics.
Unanticipated (and paradigmatic) recent developments
From among the many unanticipated and projected outcomes, we highlight those related to the paradigm shift from genetic to genomic
medicine.
• A massive volume of genotype and next-generation sequence data and information has been generated, much of which cannot yet
be interpreted [36]. The estimated cost of sequencing a single individual genome is now in the range of $100,000 and dropping fast.
• Copy number and other structural genomic variants are recognized as highly prevalent and significant contributors to human
variation and disease [37,38].
• Focus has shifted (most notably in medical oncology) from diagnostic to prognostic evaluation.
• There is now a need and ability to generate and integrate simultaneous information from many sources (DNA, RNA, protein,
epigenetic and clinical). DNA biobanking in case-control studies and genome-wide association studies has had a large impact.
• Rare variants are recognized as significant contributors to common conditions (for example, neuropsychiatric disorders).
• Direct-to-consumer genetic testing (for example 23andme, Navigenics, deCodeMe) has emerged [23].
• Ethical concerns have shifted away from autonomy as the ultimate arbiter, toward issues of common benefit [39], uncertainty and
public data [11] and open consent [40].
• The need for computational and statistical scientists, and (equally) genetic counsellors is now clearly recognized.
• The philosophy of protected open sharing of genomic (raw and processed) data in structured databases for public access is now
generally accepted, and acceptance of open-access publishing is growing.
Forecasted developments
• Generic approaches to care will be replaced by a focus on individual determinants of health, including individual genome data.
There will be a widespread shift beyond diagnosis to focus on prognosis and intervention.
• It will finally be recognized that genomics permeates all areas of medicine, making it an integral part of health education and
practice.
• Scanning and sequencing methodologies will create a shift to genotype-driven research, as unanticipated findings create a need for
phenotypic interpretation.
• The impact of the Genetics Information Non-Discrimination Act in the USA will be realized and will spread to other countries [41].
• $100 genome-wide microarrays and $1,000 genome sequences will make genotype/sequence data part of the family history,
starting with newborn genome sequencing: the reasons to know will outweigh the reasons not to know [40].
• Pharmacogenomics will be mainstream in drug development and prescription.
• New counseling paradigms will emerge to cope with more information and complexity, acknowledging elements of both Western
(non-directive) and Eastern (directive) approaches.
• Broad genome-guided application of RNA interference and stem cells (including induced pluripotent cells) will revolutionize
fertility and regenerative medicine.
• Genomics consultants will be important members of health planning teams.
Unchanged factors 
• The value of information from a thorough (and evolving) family historyDNA testing detected a hemizygous deletion of the gene
encoding desmoglein 2 (DSG2, one of several genes and loci
associated with the condition [20]). Microarray testing with
genome-wide platform coverage would have detected this
deletion, signaling the need for regular surveillance by cardiac
imaging, probably intervention with anti-arrhythmic
medications, and implantation of a cardioverter-defibrillator.
Nonetheless, with an identified mutation, C’s relatives have the
option to be tested. Carriers can benefit from early detection;
non-carriers can be relieved of the stress of uncertainty about
risk, and the costs of lifetime testing by cardiac imaging. The
clear benefits of such knowledge for improving prognosis and
prevention drive the need for research to identify other genes
associated with ARVC and their impact on phenotype.
C Ca as se e   D D: :   G Ge en ne et ti ic c   a an nd d   g ge en no om mi ic c   f fi in nd di in ng gs s   i in n   a a   c ca an nc ce er r   s sy yn nd dr ro om me e
f fa am mi il ly y
Two-year-old ‘D’ presented to the oncology service with
ataxia. Computed tomography imaging demonstrated a large
intracranial tumor, consistent with choroid plexus carci-
noma. He underwent surgical resection and multiple cycles
of chemotherapy, during which time a younger brother was
born with respiratory distress, distended abdomen and
‘blueberry muffin’ purpuric skin lesions. Further investiga-
tions demonstrated a large adrenal mass with extensive
metastases, amplification of the N-myc oncogene and (as
seen by fluorescence in situ hybridization) a deletion of
chromosome 1p; the infant was diagnosed with stage IV
neuroblastoma. Chemotherapy was ineffective, and the baby
died within three weeks. Shortly thereafter, D had a recur-
rence of an intracranial tumor with intraspinal metastases
and died. There was no other family history of cancer. A
clinical diagnosis of Li-Fraumeni-like syndrome was
confirmed for these sibs when sequencing of the p53 gene
revealed a heterozygous missense mutation (Arg158His) in
DNA from both children, and subsequently in their
unaffected mother. Whole-genome microarray analysis then
demonstrated a significant excess of copy number variants
(CNVs) in the genomes of both children, compared with a
control population, whereas their mother’s CNV frequency
was not significantly elevated [21]. These results suggest that
excessive constitutional genomic CNVs can exacerbate the
impact of a germline p53 mutation and be associated with a
more biologically aggressive tumor phenotype. The parents
are contemplating future pregnancy, and the combination of
p53 sequencing and CNV analysis will be considered for
prenatal testing.
These are but a few early representations of the impact of
genomics in medicine. Currently, Online Mendelian Inheri-
tance in Man [22] lists approximately 6,500 phenotypes with
a known or suspected Mendelian basis, most of which have
some clinical significance. Additional phenotypes have a
chromosomal or polygenic basis, and some direct our variable
responses to natural and imposed environments - including to
the medications we take. All of these phenotypes are poised to
become associated with genomic findings as the next genera-
tion of comprehensive technologies becomes integrated.
F Fu ue el li in ng g   t th he e   c cy yc cl le e
Collaboration among scientists and clinicians has fostered
remarkable progress in the development of knowledge and
technologies, yielding applications for diagnosis, prognosis
and management of patients and families. Increasingly, we
are finding solutions through cross-disciplinary consultation
in genomic medicine. This progress may be constrained,
however, by the inadequacy of educational tools to transfer
the vast amount of knowledge to health care providers. With
training that predates the genomics revolution, most
practicing medical professionals are unprepared to cope
with its pending impact. Even recent graduates have a
genetics knowledge base that is rapidly becoming outdated.
Educational interventions are needed quickly, and these may
well be driven by the questions of an internet-using public as
well as by various commercial ventures [10,23,24]. Oppor-
tunities and challenges for the genome era also need to be
recognized by policy-makers and health funding bodies [25].
Only with appropriate health care systems in place can there
be progress or benefit from the revolutionary technological
advances that genomics has to offer [23,26]. Most immediate
is the need for a new generation of technologists and genetic/
genomic counselors trained to interpret whole-genome data
[27]. Furthermore, we need technology for health infor-
mation tools, such as electronic capture and filtering, to
facilitate the collection and interpretation of medical his-
tories, genomic variants and even patient choices. Health
care professionals will need ongoing electronic resources for
point-of-care information to keep up with new knowledge.
We strongly advocate initiatives, such as that undertaken by
this journal, to promote scholarly works that combine basic
research and clinical data with consideration of their medical
applications and implications. No longer is it sufficient to be
merely descriptive, but interpretation should also be
prescriptive, with recommendations for management and
anticipatory care.
The full impact of genomic advances in health care will be
realized when the cycle of information among patients,
scientists, clinicians and caregivers is continuous, and all are
equally enlightened and empowered to make decisions. We
should expect and settle for nothing less, for genome-directed
medicine has the potential not only to mitigate the impact of
some of our genes by our knowledge of them [28], but to
provide reassurance about the vast majority of the others.
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